5nance5nance
5nance5nance
HomeScreens
LOGINGET FREE ACCOUNT

Marksans Pharma Ltd.

•
marksanspharma.comBSE: 524404NSE: MARKSANS
Market Cap₹ 14,877 Cr.
Current Price
High / Low₹ 350 / 155
Stock P/E28.8
Book Value₹ 70
Price to Book2.36
Dividend Yield0.27 %
ROCE21.1 %
ROE15.3 %
Face Value₹ 1

Add ratio to table

ABOUT

AI Sector View

AI GENERATED

Healthcare

Buy

This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.

Confidence
50%
View full sector analysis →

PROS

  • Company is almost debt free
  • Company has a healthy return on capital (ROCE) of 22.0%
  • Company has consistently been profitable over the last 5 years
  • Latest quarter profit grew 173.9% YoY, showing strong momentum
  • Company has delivered good sales growth of 16.5% CAGR over last 5 years

CONS

  • Though reporting repeated profits, the company pays out little dividend (9.8%)

* The pros and cons are machine generated based on quantitative rules.

Peer comparison

HealthcareHealthcarePharmaceuticals & Drugs
Part ofNIFTY MICROCAP250NIFTY TOTAL MKT
S.No.Name
1.SUNPHARMA1842.0036.54441957.500.872901.2326.5315299.8810.9819.1128.81
2.DIVISLAB9326.0084.64247576.000.32902.0065.503080.0027.8021.5140.75
3.TORNTPHARM4975.0086.76189233.010.76566.003.284921.0057.3219.2733.81
4.ZYDUSLIFE1119.5024.74111670.550.09990.20-34.908017.0023.9721.3924.54
5.CIPLA1365.0032.72110272.680.95785.55-39.187119.284.1316.0016.73
6.LAURUSLABS1970.3597.37106460.420.10362.07123.942026.3129.1018.2031.50
7.DRREDDY1161.0030.0796906.380.69435.60-69.108099.80-5.2113.7510.63
8.AUROPHARMA1675.4525.9796401.690.241032.0325.229150.3517.4412.7620.54
9.LUPIN2096.0017.3495842.920.861416.9816.018276.8934.2828.8629.59
10.MANKIND2277.0046.0494050.370.04574.0929.124030.5912.8913.2426.30
11.GLENMARK2416.9037.9468210.880.10482.83927.884018.4831.3520.3520.03
12.MARKSANS328.3028.7914877.370.27159.41173.89840.8035.6121.1025.34
Detailed Comparison with:

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
500531586560591642682708620720754856841
398417453450462495551582520576594661660
Operating Profit102114133110128147130127100144161195181
OPM %20.39%21.45%22.69%19.58%21.75%22.87%19.14%17.92%16.15%20.06%21.31%22.83%21.55%
101951715-03615622203525
Interest2235333366667
Depreciation14182221202021232327242425
Profit before Tax9711411310012012514311677133151200207
Tax %27.25%26.30%26.35%22.57%25.79%21.54%26.66%21.85%24.02%25.65%24.52%25.49%22.83%
Net Profit00008998105915899114149159
1.521.841.841.731.962.132.312.001.292.172.503.273.47

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
7679131,0001,1341,3761,4911,8522,1772,6232,9513,172
7348348689421,0371,2321,5131,7192,0902,3502,490
Operating Profit3378132192340259339459533601682
OPM %4.29%8.59%13.21%16.95%24.68%17.36%18.32%21.06%20.31%20.36%21.50%
1985074259506683102
Interest71010988911122425
Depreciation30272327364552748399100
Profit before Tax1550104157302248338424504561691
Tax %23.92%28.11%22.88%23.17%21.06%24.52%21.42%25.65%24.08%25.06%24.51%
Net Profit113680121239187265315383420521
EPS0.220.801.872.865.764.516.416.928.409.22—
Dividend Payout %23.16%6.21%2.68%3.50%4.34%5.54%8.51%8.67%9.53%9.76%—

COMPOUNDED SALES GROWTH

10 Years:
13%
5 Years:
16%
3 Years:
17%

COMPOUNDED PROFIT GROWTH

10 Years:
18%
5 Years:
12%
3 Years:
16%

STOCK PRICE CAGR

10 Years:
22%
5 Years:
36%
3 Years:
46%
1 Year:
89%

RETURN ON EQUITY

10 Years:
16%
5 Years:
17%
3 Years:
16%
Last Year:
15%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Corporate actions

2026

Aug 20

₹ 0.90

Rs.0.9000 per share(90%)Final Dividend

2025

Aug 1

₹ 0.80

Rs.0.8000 per share(80%)Final Dividend

2024

Sep 17

₹ 0.60

Rs.0.6000 per share(60%)Final Dividend

2023

Jun 7

₹ 0.50

Final Dividend

2022

Aug 19

₹ 0.25

Rs.0.2500 per share(25%)Final Dividend

2021

Sep 15

₹ 0.25

Rs.0.2500 per share(25%)Final Dividend

2020

Sep 22

₹ 0.10

Rs.0.1000 per share(10%)Final Dividend

2018

Sep 19

₹ 0.05

Rs.0.0500 per share(5%)Dividend

2017

Sep 19

₹ 0.05

Rs.0.0500 per share(5%)Dividend

2016

Sep 22

₹ 0.12

Rs.0.1200 per share(12%)Dividend

2015

Sep 23

₹ 0.12

Rs.0.1200 per share(12%)Dividend

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital41414141414145454545
Minority Interest6101013192120212230
3934305025958461,0681,7002,0202,4222,975
121127110313383107219286300
Trade Payables16278106110169200231268306337
30453411112124787108158162
Total Liabilities7527318029021,2281,6602,1902,6813,2403,848
2672792703033094284867769821,044
Capital Work in Progress00006175915
00000012710
190218293242404424485618846972
0000000453540645
Cash & Bank25403494212349715674704990
269193206264296457497128158183
Total Assets7527318029021,2281,6602,1902,6813,2403,848

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
355854258227172300230207458
Cash from Investing-21-39-13-60-45-84-259-141-49-248
Cash from Financing-33-21-114-1580198-69-65-71
-1015-760118941762193139

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026

Shareholding Pattern

Numbers in percentages

Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
43.8743.8743.8743.8743.8743.8743.8743.8743.87
18.5921.3121.9522.1919.8916.928.1316.7617.47
3.754.104.304.565.505.285.916.576.19
Government0.000.000.000.000.000.000.000.000.00
33.7830.7129.8729.3730.7533.9342.0932.7932.47

Documents

Corporate disclosures, annual reports, credit ratings, and concall transcripts

2026-09-07
Copy of Newspaper Publication

2026-09-07 - Marksans Pharma Limited has informed the Exchange about Copy of Newspaper Publication regarding transfer of unclaimed dividend and equity shares of the Company to the IEPF

2026-09-01
Analysts/Institutional Investor Meet/Con. Call Updates

2026-09-01 - Marksans Pharma Limited has informed the Exchange about Schedule of Investors Meet

2026-08-27
Shareholders meeting

2026-08-27 - Marksans Pharma Limited has submitted the Exchange a copy Srutinizers report along with voting result of Annual General Meeting held on August 27, 2026.

2026-08-27
Shareholders meeting

2026-08-27 - Marksans Pharma Limited has informed the Exchange regarding Proceedings of 34th Annual General Meeting held on August 27, 2026

2026-08-26
General Updates

2026-08-26 - Intimation Under Regulation 30 The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 ESG score by Crisil ESG Ratings & Analytics Ltd

2026-08-20
Analysts/Institutional Investor Meet/Con. Call Updates

2026-08-20 - Marksans Pharma Limited has informed the Exchange about Transcript of Investors/Analyst meet Q1 FY 27 Financial Results

2026-08-13
Analysts/Institutional Investor Meet/Con. Call Updates

2026-08-13 - Marksans Pharma Limited has informed the Exchange about Link of Recording of Conference call Q1 FY 27 Financial Results

2026-08-13
Copy of Newspaper Publication

2026-08-13 - Marksans Pharma Limited has informed the Exchange about Copy of Newspaper Publication for Unaudited financial results for the quarter ended June 30, 2026

2026-08-12
Press Release

2026-08-12 - Marksans Pharma Limited has informed the Exchange regarding a press release dated August 12, 2026, titled "Press Release dated 12 August 2026 on the unaudited financial results of the Company for the quarter ended 30 June 2026".

News

Recent coverage and analyst commentary for MARKSANS

Loading news…

🤖

AI Stock Analyst

Marksans Pharma Ltd.

🔒

Sign in to Chat with AI

Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.

✨ Sign In to Chat

Free 5nance Account

5nance5nance

Stock analysis and screening tool

5nanceAI © 2020-2026

Made with ❤️ in India.

Data provided by Accord Fintech

Terms & Privacy.

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nance5nance

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nanceAI © 2020-2026

Data provided by Accord Fintech

Made with ❤️ in India.

HomeScreens
Login